Efficacy of Abbott cholesterol drug in question

Links shared publicly online about this topic.

257
total visits

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zoco

View full resource at news-medical.net

Tags: Heart, Cholesterol, Cholesterol Medication, Stroke, Thrombotic Event, Drug, News

Most Recently Shared on May 30, 2011 at 7:00 am By:

News-Medical.Net

Stroke News: Efficacy of Abbott cholesterol drug in question: A latest study has found that using medication t... http://twurl.nl/gcfxn5

11 months ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

FDA Panel to Vote on Revoking Approval for Fenofibrate - QualityPoint Technologies

qualitypointtech.net — “WASHINGTON (MedPage Today) -- The FDA will ask a panel of cardiovascular experts whether it should revoke approval for Abbott's fenofibric acid (Trilipix) in light of findings from the ACCORD-Lipid trial that called into question the efficacy of using the heart drug as an add-on to statin therapy.” View full resource at qualitypointtech.net

Most Recently Shared on May 17, 2011 at 9:45 pm By:

MedicalFeed Health News Feed

FDA Panel to Vote on Revoking Approval for Fenofibrate: WASHINGTON (MedPage Today) -- The FDA will ask a panel of ... http://bit.ly/jEcRCD

11 months ago...

Retweet

Favorite

Despite FDA Warnings, The Monitoring Of High-Risk Medications Remains Unchanged | Psydir News

news.psydir.com — “A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general...” View full resource at news.psydir.com